IDC001 exploits a combined anti-tumor mechanism of PBP1510 and PBP1710. It is designed to treat cancers that express relative high level of PAUF and CTHRC1 and have developed resistance to first-line treatments, such as pancreatic cancer, liver cancer, and ovarian cancer.

Mechanism of Action


[1] CTHRC1 may serve as a prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther (2019).

[2] Elevated expression of PAUF is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. Sci Rep (2018).

[3] Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLOS ONE (2013).

[4] Efficient targeting and tumor retardation effect of PAUF-specific RNA replacement in pancreatic cancer mouse model. Cancer Lett (2014).

[5] PAUF, a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci  (2009).